The Goldman Sachs Group Increases United Therapeutics (NASDAQ:UTHR) Price Target to $302.00

United Therapeutics (NASDAQ:UTHR - Free Report) had its price target raised by The Goldman Sachs Group from $243.00 to $302.00 in a research note released on Friday, Benzinga reports. They currently have a neutral rating on the biotechnology company's stock.

Several other research firms also recently issued reports on UTHR. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. UBS Group upped their target price on United Therapeutics from $300.00 to $370.00 and gave the company a "buy" rating in a research report on Monday, July 8th. HC Wainwright lifted their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Thursday. Argus increased their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a report on Thursday. Finally, Wells Fargo & Company raised their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $370.86.

United Therapeutics Stock Up 0.0 %

Shares of NASDAQ UTHR traded up $0.05 during midday trading on Friday, hitting $374.02. 426,943 shares of the company's stock were exchanged, compared to its average volume of 466,657. The firm's fifty day simple moving average is $355.40 and its 200-day simple moving average is $316.65. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The company has a market cap of $16.64 billion, a PE ratio of 16.43, a P/E/G ratio of 1.31 and a beta of 0.57. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $377.92.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.38 EPS. Research analysts predict that United Therapeutics will post 24.75 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 269 shares of the firm's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company's stock, valued at $45,293.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, COO Michael Benkowitz sold 25,000 shares of the business's stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at $833,350.26. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the firm's stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company's stock, valued at $45,293.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 98,412 shares of company stock valued at $33,971,508. 11.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in UTHR. ClariVest Asset Management LLC lifted its stake in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after buying an additional 42 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in shares of United Therapeutics in the second quarter worth $30,000. Innealta Capital LLC purchased a new stake in shares of United Therapeutics in the second quarter valued at $33,000. USA Financial Formulas acquired a new stake in shares of United Therapeutics during the third quarter valued at $33,000. Finally, Capital Performance Advisors LLP purchased a new stake in United Therapeutics during the 3rd quarter worth about $82,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.